Skip to main content
Toggle navigation
Login
Search
Home
Systems Pharmacology (SP)
Home
Systems Pharmacology (SP)
Systems Pharmacology (SP)
Type here to filter the list
LB-023 - PATH TO REGULATORY REVIEW OF A QUANTITATIVE SYSTEM PHARMACOLOGY (QSP) MODEL
Favorite
LB-036 - UNDERSTANDING RELAXIN MECHANISMS OF ACTION THROUGH CARDIORENAL SYSTEMS PHARMACOLOGY MODELING
Favorite
PT-016 - DEVELOPMENT OF A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL TO EVALUATE THE THERAPEUTIC POTENTIAL OF ANTI-CD19 CAR-T IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Favorite
PT-022 - COMPUTATIONAL SYSTEMS PHARMACOLOGY OF PYRROLOBENZODIAZEPINE-BASED ANTIBODY-DRUG CONJUGATES
Favorite
PII-210 - A BIOMARKER-FOCUSED QSP MODEL OF COMPLEMENT ALTERNATIVE AND TERMINAL PATHWAYS TO EVALUATE POTENTIAL TARGETS FOR THERAPEUTIC IMPACT IN COMPLEMENT-ASSOCIATED DISEASES: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AS A CASE STUDY.
Favorite
PII-211 - A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL FOR PRECLINICAL TO CLINICAL TRANSLATION OF ANTIBODY-DRUG CONJUGATE (ADC) EFFICACY AND THROMBOCYTOPENIA.
Favorite
PII-212 - A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL FOR PREDICTING EFFICACY FOR A COMBINATION OF AN ANTIBODY DRUG CONJUGATE (ADC) AND A CHECKPOINT INHIBITOR (CPI) IN PHASE II/III CLINICAL TRIALS
Favorite
PII-214 - DEVELOPMENT OF A MECHANISTIC CK-PD MODEL TO QUANTITATIVELY CHARACTERIZE A CD19 DIRECTED CAR-T CELL THERAPY PRODUCT DEVELOPED USING RAPID MANUFACTURING
Favorite
PII-215 - EVALUATING THE EFFICACY OF COMBINATION OF CHECKPOINT INHIBITORS AND CHEMOTHERAPY IN LUNG CANCER USING A MECHANISTIC MODEL
Favorite
PII-218 - QSP MODEL OF RHEUMATOID ARTHRITIS, CAPTURING RANGE OF RESPONSES TO METHOTREXATE, ADALIMUMAB AND TOCILIZUMAB THERAPIES
Favorite
PII-219 - QUANTITATIVE CHARACTERIZATION OF ENHANCED TISSUE DISTRIBUTION AND INNATE KILLING POTENTIAL OF UN-ENGINEERED GAMMA DELTA Ɣδ T CELLS USING A MECHANISTIC MODEL
Favorite
PII-220 - RESPONSE TO LYMPHOCYTE DEPLETING AND LYMPHOCYTE MODULATING THERAPIES IN DIFFERENT POPULATIONS OF PATIENTS WITH MULTIPLE SCLEROSIS INVESTIGATED BY QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL
Favorite
PII-221 - TETRAVALENCY IMPACT ON BISPECIFIC ANTIBODY-ACHIEVED RECEPTOR OCCUPANCY AND TARGET DOWNREGULATION: ESTIMATION BY TRANSLATIONAL PK/RO MODEL OF CTX8371 ANTIBODY
Favorite
PII-222 - VALIDATION OF A QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL FOR CHRONIC HEPATITIS B.
Favorite
PWII-004 - DEVELOPMENT OF A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL TO EVALUATE THE THERAPEUTIC POTENTIAL OF ANTI-CD19 CAR-T IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Favorite
